Search Results
Your search for ,aLl matches 18308 pages
Showing 1601 - 1650Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma
A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy called huCART19-IL18 may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell therapy, according to recent findings from a phase I clinical trial presented by Svoboda et al at...
Risk Factors and Outcomes Among Women With Interval vs Screen-Detected Breast Cancer
In a Korean study reported in JAMA Network Open, Song et al identified risk factors for interval breast cancer vs screen-detected breast cancer and described mortality outcomes for women in the two categories. Study Details The retrospective cohort study used data from the Korean National Health...
Telehealth May Reduce Greenhouse Gas Emissions Associated With Cancer Care
Telemedicine visits for cancer care are not only more convenient and possibly easier to schedule than in-person appointments—they may also be better for the planet. These findings were presented by Andrew Hantel, MD, and colleagues at the 2024 ASCO Annual Meeting (Abstract 1522) and simultaneously...
Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma
Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...
Osimertinib for Patients With Locally Advanced EGFR-Mutated NSCLC: A New Standard of Care?
Osimertinib improved progression-free survival in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) that has been treated with chemoradiotherapy—and may be a new standard of care for this population, according to research presented by Suresh Ramalingam, MD, FACP,...
Consolidation Therapy With Durvalumab for Limited-Stage SCLC
Results from an interim analysis of the phase III ADRIATIC study demonstrated that consolidation therapy after chemoradiotherapy with durvalumab extends survival in patients with limited-stage small-cell lung cancer (SCLC) compared to the current standard-of-care treatment of chemoradiotherapy...
T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy
Fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer that progressed following endocrine therapy, according to findings from the phase III DESTINY-Breast06 trial. The research was presented by...
Perioperative Chemotherapy vs Neoadjuvant Chemoradiation in Esophageal Cancer
For patients with locally advanced esophageal adenocarcinoma that can be treated with surgery, chemotherapy administered before and after surgery improved survival compared to chemoradiotherapy before surgery. The research was presented by Hoeppner et al at the 2024 ASCO Annual Meeting (Abstract...
Adding Belantamab Mafodotin to Doublet May Slow Disease Progression or Death in Relapsed or Refractory Myeloma
According to results from the phase III DREAMM-8 trial, adding belantamab mafodotin-blmf to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma was more effective at slowing disease progression or death compared to the current standard-of-care triplet,...
CAR T-Cell Therapy in Patients With Central Nervous System Lymphoma
A chimeric antigen receptor (CAR) T-cell therapy approved for patients with large B-cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant central nervous system (CNS) lymphoma. These findings from a small cohort were presented by Nayak et ...
Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds
Although advancements in the treatment of classical Hodgkin lymphoma have increased the 5-year relative survival rate of patients with the disease to nearly 90%, dose-intensified treatment strategies may increase the risk for acute and long-term toxicities. The German Hodgkin Study Group (GHSG)...
Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) without a subsequent stem cell transplant, according to results from the phase...
American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration
The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support,...
Asciminib Shows Superior Efficacy vs Standard-of-Care Front-Line TKIs in CML
Over the past 2 decades, the development of tyrosine kinase inhibitors (TKIs) targeting the ATP-binding site of the constitutively activated tyrosine kinase in the fusion BCR::ABL1 protein has resulted in markedly improved treatment outcomes among patients with chronic myeloid leukemia (CML)....
Differences in Prostate Cancer Genomics Among U.S. Veterans
Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by Valle et al at the 2024 ASCO Annual Meeting (Abstract 5017). The research could translate into...
Cyclophosphamide May Enable More Patients With High-Risk Hematologic Malignancies to Receive Stem Cell Transplants
A novel treatment strategy using cyclophosphamide-based graft-vs-host disease prophylaxis may enable more patients with high-risk hematologic malignancies to receive stem cell transplantation from mismatched unrelated donors. These findings were presented by Al Malki et al at the 2024 ASCO Annual...
A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care
Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Motivated by His Mother’s Brain Cancer and His Own Life-Threatening Disease, a Young Physician Works to ‘Pay Back the Universe’
Like many young boys, David Fajgenbaum, MD, MBA, MSc, loved sports and dreamed about playing college football. He attained that dream, but along the way, family tragedy and a personal battle with a life-threatening disease reshaped his worldview and accelerated his ambitions as a...
Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology
Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
The National Cancer Act of 1971 Inspired a Career in Service to and Advocacy for Patients With Cancer
ASCO President for the 2024–2025 term, Robin Zon, MD, FACP, FASCO, was born and reared in Cheektowaga, a town in the western part of New York. “Cheektowaga is the Native American name for ‘land of the crabapple tree.’ Western New York was first settled by one of seven tribes belonging to the...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
Cancer Incidence, Curative Treatment, and Overall Survival in the English Prison Population
In a study reported in The Lancet Oncology, Lüchtenborg et al found that the incidence of cancer increased in the prison population in England between 1998 and 2017; those with cancer were less likely to receive curative treatment and had poorer overall survival vs patients with cancer in the...
Be Prepared: A Patient Perspective
I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...
Early Breast Cancer: ALND or SLNB for ypN-Positive Disease After Neoadjuvant Chemotherapy
In an analysis of clinical trials reported in a research letter in JAMA Oncology, Brooks et al found no differences in long-term outcomes with the use of axillary lymph node dissection (ALND) vs sentinel lymph node biopsy (SLNB)—usually paired with adjuvant radiotherapy—among patients with breast...
Can Exercise Boost the Efficacy of Rituximab in Treatment of CLL?
Sessions of moderate-to-vigorous exercise may improve the efficacy of antibody therapies, such as rituximab, used to treat chronic lymphocytic leukemia (CLL), according to a recent study published by Collier-Bain et al in Brain, Behavior, and Immunity. The findings may demonstrate the potential of...
Patient Characteristics May Impact Results of AI Algorithm–Interpreted Screening Mammograms
Investigators have found that patient characteristics such as age and race may influence false-positive results from artificial intelligence (AI)-interpreted screening mammograms, according to a recent study published by Nguyen et al in Radiology. Background Although preliminary data suggested that ...
ASCO Issues Updated Guidelines for Stage IV NSCLC With and Without Driver Alterations
ASCO has issued new evidence-based updates to two living guidelines on the treatment of stage IV NSCLC with and without driver alterations.1,2 Updated Recommendations: Stage IV NSCLC With Driver Alterations The most “extensive work” in the updates occurred in the guideline on stage IV NSCLC with...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
NCCN Appoints Chair, Vice-Chair of Board of Directors
The National Comprehensive Cancer Network (NCCN®) has announced the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022. “The exemplary leadership from our Board...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
A Look Back on an Impactful and Inspiring Presidential Year
Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...
Applying the Power of Knowledge to Drive Positive Change in Oncology Care
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during the 2024 ASCO Annual Meeting, May 31 to June 4, 2024, in Chicago and online. Dr. Zon began her 4-year term in June 2023 as President-Elect and will...
We Have an IDEA: United in the Fight Against Cancer
On behalf of 2024 International Development and Education Award (IDEA) awardees, we received the decision of our acceptance in this outstanding training program offering mentorship and educational opportunities for early-career oncologists and cancer researchers with great interest. This will...
Partnering With Patients Is Integral for a Good Outcome
About 3 years ago, I woke up from a sound sleep and was having a hard time breathing. It felt like someone was sitting on my neck, constricting my airways. I could feel prominent swelling in my lymph nodes along my neck and clavicle, and I was scared. A trip to the emergency room proved fruitless, ...
Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers
Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...
Study Explores How Partner Relationships Impact the Well-Being of Breast Cancer Survivors
Diagnosis and treatment of breast cancer place significant stress on survivors, their partners, and their relationships. A recent study from researchers at the Regenstrief Institute and Indiana University (IU)’s Schools of Nursing, Science, and Medicine is one of the first to examine the impact of...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
On April 30, 2024, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer.1 The USPSTF now recommends that all women undergo screening for breast cancer every other year starting at age 40 and continuing through age 74. More...
Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer
For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both endocrine therapies and CDK4/6 inhibitors is common, and new approaches are needed to counteract...
Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...
CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma
Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...
HPV Screening Intervals for Cervical Cancer May Be Safely Extended Beyond Current 5-Year Recommendation, Study Finds
A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...
Survival Outcomes Following Adjuvant Therapy in Patients With Clinical T2N0 Rectal Adenocarcinoma
Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented by Kripalani et al at Digestive Disease Week (DDW) 2024 (Abstract 439). Background Patients with clinical T2N0 rectal adenocarcinoma have disease that has spread past the...
Metformin May Help Reduce the Risk of Developing Myeloproliferative Neoplasms
Treatment with metformin may be associated with a lower risk of developing myeloproliferative neoplasms over time, according to a recent study published by Kristensen et al in Blood Advances. Background Myeloproliferative neoplasms are a group of diseases that develop over long periods of time and...
Advanced Gastric or Gastroesophageal Junction Cancer: Addition of Relatlimab to Immunochemotherapy
In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...
Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...
